Remove Containment Remove Contamination Remove Marketing Remove Production
article thumbnail

Chemical synthesis: containment challenges for HPAPI handling

Pharmaceutical Technology

This process is used to manufacture pharmaceutical products with low molecular weights in large batches within a short timescale. These facilities are often multi-use CMO facilities, which combined with the use of HPAPIs, require stringent containment solutions to prevent cross-contamination. Chemical synthesis solutions.

article thumbnail

Mitigating the risks of cross-contamination during Oral Solid Dose (OSD) manufacturing

Pharmaceutical Technology

There are a number of reasons why OSD forms dominate the market, not least because they are simple to administer, and it is easy to differentiate one OSD product from another. This heightens the risk of cross contamination, requiring effective containment solutions, especially when handling highly potent powders.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How API CMOs can improve containment capabilities without facility acquisition

Pharmaceutical Technology

According to GlobalData analysis, specialist small molecule API capabilities such as containment or controlled substances are driving large contract manufacturing organisations (CMOs) to acquire facilities. Flexible containment solutions for potent APIs. Partnering with containment experts.

article thumbnail

A winning combination: The benefits of micronization and containment in a single installation

Pharmaceutical Technology

The number of high-potency drug approvals has increased over the last decade, driven by the increasing use of APIs (Active Pharmaceutical Ingredients) in the pipeline and among marketed drugs. Containment challenges and opportunities High containment facilities guard against exposure to extremely potent products and cross-contamination.

article thumbnail

The rising importance of containment in small molecule drug development

Pharmaceutical Technology

Cross-contamination of standard products with highly potent ones is another key concern. On the other hand, the current trend is for fully closed systems that use negative pressure to keep particles contained inside isolators. Many companies are now prioritising investments in containment systems, GlobalData research shows.

article thumbnail

Some Talc Products Contain Asbestos: Study

The Pharma Data

30, 2020 – Nearly 15% of talc-based cosmetic products analyzed in a recent study contained asbestos. She noted that EWG’s online database has identified more than 2,000 personal care products that contain talc, including more than 1,000 loose or pressed powders that could pose an inhalation risk. MONDAY, Nov.

article thumbnail

Container Closure Integrity Testing: A Necessity for Pharmaceutical Industry

Roots Analysis

Considering patient’s health and safety, the drug products are expected to be free from microbial contamination and should be safe for use throughout the drug’s life cycle. Therefore, several quality checks are performed to ensure product’s sterility and stability. Expansion of Container Closure Integrity Testing Network.